Concepedia

Publication | Closed Access

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease

DOI

270

Citations

22

References

2014

Year

J.‐F. Yale, G. Bakris, Bertrand Cariou, Elias David‐Neto, Dennis K. Yue, Ewa Wajs, K. Figueroa, Joel Jiang, Ga‐Lai Law, Keith Usiskin,
Diabetes Obesity and Metabolism

Abstract

Canagliflozin improved glycaemic control and was generally well tolerated in patients with T2DM and within a subset of Stage 3 CKD over 52 weeks.

References

YearCitations

Page 1